2,2,2-Trifluoroethyl Chlorooxoacetate—Universal Reagent for One-Pot Parallel Synthesis of N1-Aryl-N2-alkyl-Substituted Oxamides
摘要:
A one-pot parallel synthesis of N-1-aryl-N-2-alkyl-substituted oxamides with 2,2,2-trifluoroethyl chlorooxoacetate was developed. The synthesis of a library of 45 oxamides revealed higher efficiency of this reagent over the known ethyl chlorooxoacetate. The reagent was successfully used to prepare the known oxamide-containing HIV entry inhibitors.
Photometric Characterization of the Reductive Amination Scope of the Imine Reductases from<i>Streptomyces tsukubaensis</i>and<i>Streptomyces ipomoeae</i>
reductive amination catalyzed by two promising imine reductases is established in a rapid photometric NADPH assay. Substrates ranging from aldehydes to ketones and from primary to secondaryamines are accepted, thus giving access to various secondary and tertiaryamine products.
2-PROPYNYL ADENOSINE ANALOGS WITH MODIFIED 5'-RIBOSE GROUPS HAVING A2A AGONIST ACTIVITY
申请人:Rieger Jayson M.
公开号:US20090253647A1
公开(公告)日:2009-10-08
The invention provides compounds having the following general formula (I):
wherein X, R
1
, R
2
, R
7
and Z are as described herein.
本发明提供具有以下一般式(I)的化合物:其中X,R1,R2,R7和Z如本文所述。
2-POLYCYCLIC PROPYNYL ADENOSINE ANALOGS HAVING A2A AGONIST ACTIVITY
申请人:Rieger Jayson M.
公开号:US20090298788A1
公开(公告)日:2009-12-03
The invention provides compounds having the following general formula (I):
wherein X, R
1
, R
2
, R
7
and Z are as described herein.
本发明提供具有以下一般式(I)的化合物:其中X、R1、R2、R7和Z如本文所述。
Aminopyridine Derivatives
申请人:Evans David Michael
公开号:US20100076015A1
公开(公告)日:2010-03-25
The present invention provides compounds of formula (I):
compositions comprising such compounds; the use of such compounds in therapy (such as asthma or COPD); and methods of treating patients with such compounds; wherein R
1
-R
11
are as defined herein.
2-propynyl adenosine analgos with modified 5'-ribose groups having A2A agonist activity
申请人:University Of Virginia Patent Foundation
公开号:EP2266994A1
公开(公告)日:2010-12-29
A therapeutic composition comprising a compound having the formula
or a pharmaceutically acceptable salt thereof in combination with a pharmaceutically acceptable carrier.